Company intelligence / Profile preview

Opsona Therapeutics

Ownership: Private
Employees: ~19
Development stage: Phase 2

Overview

The company conducted clinical trials for its lead product OPN-305 (Tomaralimab), a humanized IgG4 monoclonal antibody targeting TLR2, in renal transplant patients and myelodysplastic syndrome. The company went into liquidation in 2019 after unsuccessful clinical trials and failure to find a buyer for OPN-305.

Therapeutic areas: OncologyCardiovascularNephrologyImmunologyEndocrinologyHematologyNeurology
Modalities: Monoclonal antibodiesbiologicssmall molecules
Industry: Biotech

Drug pipeline

3 assets

tomaralimab

Phase 2

Indications: Myelodysplastic syndrome, Delayed graft function

2 more assets in the full pipeline.

Request access →

Partnerships

Wyeth

Beyond the preview

Go deeper on Opsona Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Opsona Therapeutics.

Explore the full profile